Has There Been A Sea Change In Trial Diversity Efforts?
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
You may also be interested in...
Ponda Motsepe-Ditshego, who leads Amgen’s clinical trial diversity efforts, admits they are in early stages but noted progress internally and externally at better representing diverse patient groups.
PhRMA is funding an initiative to establish a network of sustainable, community-based trial sites. During 18-month proof of concept phase, 10 sites will receive training, technical support and mentorship.
Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.